NXL Market Analysis

News & Sentiment

50 articles · sorted by date
Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Fundamentals

Updated daily after market close
P/E ratio
EPS (TTM)$-13.800.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$4.1MMicro cap

Valuation

Forward P/E
PEG ratio
P/B
2.60
P/S (TTM)
19.66
EV/EBITDA
0.02

Profitability & growth

ROE (TTM)
-240.2%
Operating margin
-18480.0%
Revenue growth YoY
-82.8%
Dividend yield
Beta
3.98
Last earnings
Aug 12, 2026 · Estimate $-0.10 · Reported $-0.11
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About Nexalin Technology Inc.

Company profile

Nexalin Technology Inc. is a pioneering medical technology firm dedicated to transforming the treatment of neurological and psychiatric disorders through its proprietary transcranial electrical stimulation devices. By offering non-invasive solutions for prevalent mental health issues such as anxiety, depression, and substance addiction, the company underscores its commitment to improving patient outcomes and advancing accessible mental health care. With a robust research background and a strategic focus on tapping into the rising demand for innovative healthcare solutions, Nexalin is…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
1776 YORKTOWN, HOUSTON, TX
Fiscal year end
December
Latest quarter
Jun 30, 2026
Market cap$4.1M
Shares outstanding$829400
52W high$60.00
52W low$4.51

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer